10 Key Factors About Personalized Depression Treatment You Didn't Lear…
Hudson Haskins
0
3
10.10 18:24
Personalized depression treatment ect Treatment
Traditional treatment and medications are not effective for a lot of people suffering from depression. The individual approach to treatment could be the solution.
Cue is a digital intervention platform that converts passively collected smartphone sensor data into personalized micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to identify their feature predictors and uncover distinct features that deterministically change mood with time.
Predictors of Mood
Depression is among the world's leading causes of mental illness.1 However, only half of people suffering from the disorder receive treatment1. To improve outcomes, clinicians need to be able to recognize and treat patients with the highest likelihood of responding to certain treatments.
Personalized depression treatment is one method to achieve this. By using mobile phone sensors and an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to determine biological and behavioral predictors of response.
The majority of research done to the present has been focused on clinical and sociodemographic characteristics. These include demographics like age, gender and education and clinical characteristics such as symptom severity and comorbidities, as well as biological markers.
Very few studies have used longitudinal data to determine mood among individuals. Many studies do not take into account the fact that mood can differ significantly between individuals. Therefore, it is crucial to develop methods that permit the determination and quantification of the personal differences between mood predictors treatments, mood predictors, etc.
The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to recognize patterns of behavior and emotions that are unique to each person.
In addition to these modalities the team also developed a machine-learning algorithm that models the dynamic predictors of each person's depressed mood. The algorithm integrates the individual differences to create a unique "digital genotype" for each participant.
The digital phenotype was associated with CAT-DI scores, a psychometrically validated symptom severity scale. The correlation was low, however (Pearson r = 0,08, BH adjusted P-value 3.55 10 03) and varied widely between individuals.
Predictors of symptoms
Depression is a leading reason for disability across the world, but it is often not properly diagnosed and treated. In addition an absence of effective treatments and stigma associated with depressive disorders prevent many from seeking treatment.
To facilitate personalized treatment, identifying patterns that can predict symptoms is essential. However, current prediction methods are based on the clinical interview, which is not reliable and only detects a tiny number of features that are associated with depression.2
Using machine learning to integrate continuous digital behavioral phenotypes of a person captured by smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory the CAT-DI) with other predictors of severity of symptoms can increase the accuracy of diagnostics and the effectiveness of treatment for depression. These digital phenotypes allow continuous, high-resolution measurements as well as capture a wide variety of unique behaviors and activity patterns that are difficult to document using interviews.
The study enrolled University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. who were enrolled in the Screening and Treatment for anxiety depression treatment and Depression (STAND) program29 that was created under the UCLA depression treatment diet Grand Challenge. Participants were directed to online support or clinical care according to the degree of their depression. Patients with a CAT DI score of 35 65 were given online support via a coach and those with scores of 75 patients were referred to psychotherapy in person.
At the beginning, participants answered a series of questions about their personal demographics and psychosocial features. These included sex, age and education, as well as work and financial status; whether they were divorced, partnered or single; their current suicidal ideas, intent or attempts; as well as the frequency at the frequency they consumed alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale ranging from zero to 100. CAT-DI assessments were conducted each other week for the participants who received online support and weekly for those receiving in-person care.
Predictors of Treatment Response
Personalized depression treatment is currently a major research area, and many studies aim at identifying predictors that enable clinicians to determine the most effective medications for each person. Particularly, pharmacogenetics can identify genetic variants that influence how the body metabolizes antidepressants. This lets doctors select the medication that are most likely to work for each patient, reducing time and effort spent on trials and errors, while avoid any negative side negative effects.
Another approach that is promising is to develop prediction models combining the clinical data with neural imaging data. These models can be used to determine the most effective combination of variables predictors of a specific outcome, such as whether or not a particular medication will improve the mood and symptoms. These models can be used to predict the patient's response to treatment, allowing doctors to maximize the effectiveness.
A new generation of machines employs machine learning techniques such as the supervised and classification algorithms, regularized logistic regression and tree-based methods to combine the effects from multiple variables and increase the accuracy of predictions. These models have been demonstrated to be effective in predicting the outcome of treatment, such as response to antidepressants. These models are getting more popular in psychiatry, and it is expected that they will become the norm for future clinical practice.
In addition to the ML-based prediction models, research into the mechanisms that cause depression is continuing. Recent findings suggest that the disorder is connected with dysfunctions in specific neural circuits. This suggests that an individualized depression treatment will be based on targeted treatments that target these circuits to restore normal function.
One method to achieve this is by using internet-based programs that can provide a more individualized and tailored experience for patients. For example, one study discovered that a web-based treatment was more effective than standard care in alleviating symptoms and ensuring the best quality of life for patients with MDD. A controlled study that was randomized to an individualized treatment for depression treatment cbt revealed that a significant number of patients saw improvement over time and fewer side effects.
Predictors of side effects
In the treatment of depression one of the most difficult aspects is predicting and determining the antidepressant that will cause no or minimal negative side negative effects. Many patients are prescribed a variety medications before settling on a treatment that is safe and effective. Pharmacogenetics offers a fascinating new method for an efficient and specific approach to selecting antidepressant treatments.
Several predictors may be used to determine which antidepressant to prescribe, including genetic variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and co-morbidities. However, identifying the most reliable and valid predictive factors for a specific treatment is likely to require controlled, randomized trials with much larger samples than those typically enrolled in clinical trials. This is due to the fact that the identification of moderators or interaction effects may be much more difficult in trials that only take into account a single episode of treatment per patient, rather than multiple episodes of treatment over time.
Additionally the prediction of a patient's response will likely require information about the severity of symptoms, comorbidities and the patient's own perception of effectiveness and tolerability. At present, only a handful of easily assessable sociodemographic variables and clinical variables seem to be consistently associated with response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.
The application of pharmacogenetics in treatment for depression is in its infancy and there are many hurdles to overcome. First is a thorough understanding of the genetic mechanisms is essential as well as a clear definition of what is a reliable predictor of treatment response. Additionally, ethical issues such as privacy and the appropriate use of personal genetic information should be considered with care. In the long-term the use of pharmacogenetics could be a way to lessen the stigma that surrounds mental health treatment and to improve the outcomes of those suffering with depression. But, like all approaches to psychiatry, careful consideration and application is necessary. At present, it's best to offer patients various chronic depression treatment medications that are effective and urge them to talk openly with their doctors.
Traditional treatment and medications are not effective for a lot of people suffering from depression. The individual approach to treatment could be the solution.
Cue is a digital intervention platform that converts passively collected smartphone sensor data into personalized micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to identify their feature predictors and uncover distinct features that deterministically change mood with time.
Predictors of Mood
Depression is among the world's leading causes of mental illness.1 However, only half of people suffering from the disorder receive treatment1. To improve outcomes, clinicians need to be able to recognize and treat patients with the highest likelihood of responding to certain treatments.
Personalized depression treatment is one method to achieve this. By using mobile phone sensors and an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to determine biological and behavioral predictors of response.
The majority of research done to the present has been focused on clinical and sociodemographic characteristics. These include demographics like age, gender and education and clinical characteristics such as symptom severity and comorbidities, as well as biological markers.
Very few studies have used longitudinal data to determine mood among individuals. Many studies do not take into account the fact that mood can differ significantly between individuals. Therefore, it is crucial to develop methods that permit the determination and quantification of the personal differences between mood predictors treatments, mood predictors, etc.
The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to recognize patterns of behavior and emotions that are unique to each person.
In addition to these modalities the team also developed a machine-learning algorithm that models the dynamic predictors of each person's depressed mood. The algorithm integrates the individual differences to create a unique "digital genotype" for each participant.
The digital phenotype was associated with CAT-DI scores, a psychometrically validated symptom severity scale. The correlation was low, however (Pearson r = 0,08, BH adjusted P-value 3.55 10 03) and varied widely between individuals.
Predictors of symptoms
Depression is a leading reason for disability across the world, but it is often not properly diagnosed and treated. In addition an absence of effective treatments and stigma associated with depressive disorders prevent many from seeking treatment.
To facilitate personalized treatment, identifying patterns that can predict symptoms is essential. However, current prediction methods are based on the clinical interview, which is not reliable and only detects a tiny number of features that are associated with depression.2
Using machine learning to integrate continuous digital behavioral phenotypes of a person captured by smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory the CAT-DI) with other predictors of severity of symptoms can increase the accuracy of diagnostics and the effectiveness of treatment for depression. These digital phenotypes allow continuous, high-resolution measurements as well as capture a wide variety of unique behaviors and activity patterns that are difficult to document using interviews.
The study enrolled University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. who were enrolled in the Screening and Treatment for anxiety depression treatment and Depression (STAND) program29 that was created under the UCLA depression treatment diet Grand Challenge. Participants were directed to online support or clinical care according to the degree of their depression. Patients with a CAT DI score of 35 65 were given online support via a coach and those with scores of 75 patients were referred to psychotherapy in person.
At the beginning, participants answered a series of questions about their personal demographics and psychosocial features. These included sex, age and education, as well as work and financial status; whether they were divorced, partnered or single; their current suicidal ideas, intent or attempts; as well as the frequency at the frequency they consumed alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale ranging from zero to 100. CAT-DI assessments were conducted each other week for the participants who received online support and weekly for those receiving in-person care.
Predictors of Treatment Response
Personalized depression treatment is currently a major research area, and many studies aim at identifying predictors that enable clinicians to determine the most effective medications for each person. Particularly, pharmacogenetics can identify genetic variants that influence how the body metabolizes antidepressants. This lets doctors select the medication that are most likely to work for each patient, reducing time and effort spent on trials and errors, while avoid any negative side negative effects.
Another approach that is promising is to develop prediction models combining the clinical data with neural imaging data. These models can be used to determine the most effective combination of variables predictors of a specific outcome, such as whether or not a particular medication will improve the mood and symptoms. These models can be used to predict the patient's response to treatment, allowing doctors to maximize the effectiveness.
A new generation of machines employs machine learning techniques such as the supervised and classification algorithms, regularized logistic regression and tree-based methods to combine the effects from multiple variables and increase the accuracy of predictions. These models have been demonstrated to be effective in predicting the outcome of treatment, such as response to antidepressants. These models are getting more popular in psychiatry, and it is expected that they will become the norm for future clinical practice.
In addition to the ML-based prediction models, research into the mechanisms that cause depression is continuing. Recent findings suggest that the disorder is connected with dysfunctions in specific neural circuits. This suggests that an individualized depression treatment will be based on targeted treatments that target these circuits to restore normal function.
One method to achieve this is by using internet-based programs that can provide a more individualized and tailored experience for patients. For example, one study discovered that a web-based treatment was more effective than standard care in alleviating symptoms and ensuring the best quality of life for patients with MDD. A controlled study that was randomized to an individualized treatment for depression treatment cbt revealed that a significant number of patients saw improvement over time and fewer side effects.
Predictors of side effects
In the treatment of depression one of the most difficult aspects is predicting and determining the antidepressant that will cause no or minimal negative side negative effects. Many patients are prescribed a variety medications before settling on a treatment that is safe and effective. Pharmacogenetics offers a fascinating new method for an efficient and specific approach to selecting antidepressant treatments.
Several predictors may be used to determine which antidepressant to prescribe, including genetic variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and co-morbidities. However, identifying the most reliable and valid predictive factors for a specific treatment is likely to require controlled, randomized trials with much larger samples than those typically enrolled in clinical trials. This is due to the fact that the identification of moderators or interaction effects may be much more difficult in trials that only take into account a single episode of treatment per patient, rather than multiple episodes of treatment over time.
Additionally the prediction of a patient's response will likely require information about the severity of symptoms, comorbidities and the patient's own perception of effectiveness and tolerability. At present, only a handful of easily assessable sociodemographic variables and clinical variables seem to be consistently associated with response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.
The application of pharmacogenetics in treatment for depression is in its infancy and there are many hurdles to overcome. First is a thorough understanding of the genetic mechanisms is essential as well as a clear definition of what is a reliable predictor of treatment response. Additionally, ethical issues such as privacy and the appropriate use of personal genetic information should be considered with care. In the long-term the use of pharmacogenetics could be a way to lessen the stigma that surrounds mental health treatment and to improve the outcomes of those suffering with depression. But, like all approaches to psychiatry, careful consideration and application is necessary. At present, it's best to offer patients various chronic depression treatment medications that are effective and urge them to talk openly with their doctors.
